Skip to content

Apellis Pharmaceuticals Inc

APLS

Latest QuantConomy context for APLS: asset profile, market coverage, scored signals, and source-linked SEC insider filings when available.

Asset class
stock
Primary venue
NASDAQ
Recent signals
3
SEC filings
20
Asset profile

Apellis Pharmaceuticals Inc

QuantConomy has a structured record for APLS. More descriptive asset metadata will appear here when the platform record includes it.

Symbol
APLS
Name
Apellis Pharmaceuticals Inc
Coverage
3 market/data records
Sources
fmp alphavantage alpaca sec nasdaq
Latest signal rows

Recent signals for APLS

Scored rows are pulled from the same signal API used by the digests.

Signal Direction Score Observed Reason
earnings release
neutral
40
Jan 12, 12:00 AM APLS filed an earnings release (8-K Item 2.02 - Results of Operations and Financial Condition) on 2026-01-12. Release-event signal only: confirms results were published, not the figures vs. estimates (no surprise/guidance read).
material agreement
very bearish
100
May 14, 12:50 PM APLS filed 8-K: Modification to Rights of Security Holders, Change in Control, Director or Officer Changes - 9 material events - [very strong very bearish signal]
executive change
neutral
75
May 4, 11:10 AM APLS filed 8-K: Director or Officer Changes - 1 material event - [strong neutral signal]

EARNINGS signals are experimental: currently limited to neutral pre-earnings calendar awareness (no transcript analysis).

Market coverage

Market Exchange Source Asset record
APLS NASDAQ fmp Apellis Pharmaceuticals, Inc.
APLS NASDAQ alphavantage Apellis Pharmaceuticals Inc
APLS NASDAQ alpaca Apellis Pharmaceuticals, Inc. Common Stock

Recent insider transactions

Buys, last 90d
0
Sells, last 90d
0
Rows
20
Date Insider Role Type Shares Price Value Filing
May 14, 2026 O'Brien Stephanie Monaghan Director other 25,666 4 on EDGAR
May 14, 2026 WHEELER CRAIG A Director other 24,444 4 on EDGAR
May 14, 2026 Nicholson Nur Chief Technical Officer other 116,338 4 on EDGAR
May 14, 2026 Walbert Keli Director other 17,051 4 on EDGAR
May 14, 2026 Deschatelets Pascal Chief Scientific Officer other 1,177,222 4 on EDGAR
May 14, 2026 Dolsten Mikael Director other 14,312 4 on EDGAR
May 14, 2026 Sullivan Timothy Eugene Chief Financial Officer other 140,945 4 on EDGAR
May 14, 2026 Dunlop A. Sinclair Director other 161,567 4 on EDGAR
May 14, 2026 FONTEYNE PAUL R. Director other 30,666 4 on EDGAR
May 14, 2026 Chopas James George VP/Chief Accounting Officer other 65,955 4 on EDGAR
May 14, 2026 Baumal Caroline Chief Medical Officer other 86,525 4 on EDGAR
May 14, 2026 Machiels Alec Director other 384,989 4 on EDGAR
May 14, 2026 DeLong Mark Jeffrey Chief Business & Strat Officer other 114,591 4 on EDGAR
May 14, 2026 Watson David O. General Counsel other 144,517 4 on EDGAR
May 14, 2026 Francois Cedric Chief Executive Officer other 425,968 4 on EDGAR
May 14, 2026 Boucher Kelley Chief People Officer other 127,804 4 on EDGAR
May 14, 2026 MELTZER LESLIE Chief Research and Development other 107,024 4 on EDGAR
May 14, 2026 Chan Gerald Director other 25,666 4 on EDGAR
Apr 29, 2026 Baumal Caroline Chief Medical Officer gift 900 $0.00 $0 4 on EDGAR
Apr 17, 2026 Sullivan Timothy Eugene Chief Financial Officer gift 11,096 $0.00 $0 4 on EDGAR

Source: SEC filings via QuantConomy. Not investment advice.

Get the data

Query APLS context like a database.

These rows come from the QuantConomy signal, asset, market, and SEC filings API surfaces, also available to AI agents over MCP.

No spam, no noise. Just the launch and the occasional preview.

More: All insider trades · How to read a Form 4 · API access